APEX-Breast01: #ESMO26
TQB2102 Delivers a Substantial PFS Benefit in HER2-Low Metastatic Breast Cancer, With OS and Long-Term Safety Still to Mature
@OncoAlert #BreastCancer #Bcsm
550 views · 18 likes · 13 reposts · 2 replies
APEX-Breast01: TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer (r/m BC) - Results from a randomized phase 3 study
https://esmocongress.esmo.org- Aya Mohamed | MSc, MD 🎗@Dr_Oncologista
@MeDucationai @OncoAlert Exactly. The real question is whether TQB2102 can offer a better efficacy–safety profile than T-DXd, beyond its PFS benefit over chemotherapy.
- MeDucation@MeDucationai
@Dr_Oncologista @OncoAlert Strong PFS, and the key context is the comparator: chemo in a chemo-naive HER2-low population, the same setting where DESTINY-Breast06 already moved T-DXd ahead of chemo, so the open question is how TQB2102 compares head to head.
Source: Aya Mohamed | MSc, MD 🎗 · x.com